Home Healthcare Pharmaceuticals Stroke Disorder and Treatment Market

Stroke Disorder and Treatment Market Size, Share & Trends Analysis Report By Type (Ischemic stroke, Hemorrhagic strokes), By Medicine (Anticoagulants, Anti-hypertensive), By Treatment (Tissue plasminogen activator (tPA), Endovascular procedures) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: August 24, 2026 | Author: Dhanashri Chandgude | Format:

Stroke Disorder and Treatment Market Size

The global stroke disorder and treatment market size was valued at USD 23.77 billion in 2025 and is projected to grow from USD 25.60 billion in 2026 to USD 46.38 billion by 2034, registering a CAGR of 7.71% during the forecast period from 2026 to 2034. North America dominated the stroke disorder and treatment market with a market share of 38% in 2025.

The global stroke disorder and treatment market is largely boosted by the surging incidence of strokes globally, especially in lower and lower-middle-income nations. In light of these surging stroke incidences, several organizations across the world are initiating awareness campaigns to tackle the stroke disorder. Moreover, there has been growing research for developing novel treatments for stroke, which is expected to create opportunities for market expansion.

A stroke, also called a "brain attack," occurs when a blood artery in the brain bursts or is blocked, cutting off blood flow to part of the brain. In either scenario, cerebral tissue is either damaged or destroyed. Permanent brain damage, long-term disability, or even mortality may result from a stroke. A stroke constitutes an urgent medical condition. Mild weakness may progress to paralysis or numbness affecting a single side of the body or face during stroke.

High blood pressure is one of the primary clinical risk factors associated with stroke. Tobacco use, physical inactivity, alcohol consumption, an unhealthy diet, atrial fibrillation, elevated blood lipid levels, genetic predisposition, obesity, stress, and depression are additional risk factors. The long-term impact of a stroke may include physical impairment, impaired communication, unemployment, reduced income, and severed social connections. Accelerated treatment access enhances recovery and saves lives.

Stroke Disorder and Treatment Market Size

Download a Free Sample To learn more about this report.

Stroke Disorder and Treatment Market Segmentation

By Type

The ischemic stroke segment is the largest revenue contributor to the market and is expected to expand over the forecast period. An ischemic stroke is a cerebrovascular event characterized by the obstruction or reduction of blood flow to a specific region of the brain, commonly caused by a blood clot or the development of atherosclerosis, which involves the accumulation of lipid deposits inside the arterial walls. The obstruction hinders the supply of oxygen and nutrients to the cerebral cells, resulting in impairment and, potentially, the demise of cerebral tissue in the impacted region. Ischemic strokes are the most prevalent form of stroke, constituting roughly 87% of the total number of strokes. This drives the segment growth in the market.

Stroke Disorder and Treatment Market Size By Segments

Request Customizationto receive a tailored report.

By Medicine

The anticoagulants segment dominates the global market and is expected to expand substantially over the forecast period. Anticoagulants, which are frequently prescribed to reduce the risk of stroke in specific individuals, are a class of blood-thinning drugs. The key players in the market are consistently striving to introduce new anticoagulants for treating stroke, driving the market growth.

  • For instance, in February 2023, Bayer, a German pharmaceutical company, was granted expedited status by the U.S. Food and Drug Administration (FDA) for its novel blood thinner, asundexian. This medication is specifically developed to mitigate the occurrence of specific stroke types. Bayer's pursuit of this regulatory milestone aligns with its objective to build upon the achievements of its anticoagulant drug, Xarelto.

By Treatment

The tissue plasminogen activator (tPA) segment owns the highest market share and is expected to grow substantially during the forecast period. Tissue Plasminogen Activator (tPA) is an enzyme intrinsic to the human body and essential for fibrinolysis, the process by which blood clots dissolve. tPA is generated and secreted by specific cells within the body and endothelial cells that line blood vessels. Therapeutically, tPA is predominantly employed to treat specific medical conditions, including acute myocardial infarctions and ischemic strokes. During such circumstances, tPA may be utilized as a pharmaceutical agent to facilitate the dissolution of blood clots, impeding the supply of vital organs such as the brain or heart. This could reduce tissue injury and preserve lives.

Stroke Disorder and Treatment Market Share By Segments

Speak to an Analystto discuss market opportunities.

Regional Insights

North America is the most significant global stroke disorder and treatment market shareholder over the forecast period. The regional market dominance can be ascribed to the flourishing prevalence of stroke disease.

  • For instance, according to CDC, Stroke accounted for one in every six fatalities caused by cardiovascular disease in 2021. In the United States, stroke incidence occurs at a rate of one occurrence every 40 seconds for an individual. Every 3 minutes and 14 seconds, two persons succumb to the fatal consequences of a stroke. Likewise, it is worth noting that a staggering number of 795,000 persons experience strokes yearly in the United States. Such a high prevalence of stroke is driving the global stroke disorder and treatment market.

Furthermore, stroke is predominantly caused by hypertension, obesity, diabetes, tobacco use, and elevated cholesterol levels. At least one of the following conditions or habits affects one in every three adults in the United States. This is expected to expedite the regional market growth. In addition, there has been a surge in R&D for stroke and stroke-associated treatment.

  • For instance, in October 2023, the National Institutes of Health awarded Associate Professor Hui-Ting Goh, Ph.D., and Professor Emeritus Elaine Jackson of the School of Physical Therapy at the Dallas Center a USD 372,870 three-year grant to support their research project titled "Behavioral and Neural Correlates of Post-Stroke Fatigue." All these factors together contribute to market growth in North America.
North America Stroke Disorder and Treatment Market Revenue Share 2025

Unlock Regional Insightsto access country-level data, & regional trends.

Asia-Pacific Stroke Disorder and Treatment Market Trends

The Asia-Pacific region is growing significantly owing to the huge target population base, advancements in healthcare infrastructure, soaring disposable income, and growing R&D in stroke management. Various awareness campaigns are conducted in the region to lessen the burden of stroke in Asia-Pacific.

  • For instance, the World Health Organization (WHO) South-East Asia Region, in collaboration with Christian Medical College (CMC), Ludhiana, Punjab, India, has initiated a program known as the "Technical Support for Mentoring of Stroke Care Improvement Program." This initiative spans across six countries in the South-East Asia region. With the assistance of the WHO Sri Lanka office and the Non-communicable Diseases unit of the Ministry of Health, Sri Lanka is also participating in the aforementioned program in collaboration with the National Stroke Association. A stroke care delivery evaluation in Sri Lanka was conducted from May to December 2022 as an initial step of the project. Such programs are expected to boost the market growth.

The European region is mainly boosted by the elevated per capita income, favorable reimbursement policies, flourishing geriatric population, and increased health awareness. In addition, the favorable government initiatives in this region support stroke awareness in driving market growth.

  • For instance, in May 2021, health ministries throughout Europe were urged to sign the Declaration for Action on the Stroke Action Plan for Europe to combat one of the primary causes of disability and death. This initiative, spearheaded by the Stroke Alliance for Europe (SAFE) and The European Stroke Organisation (ESO), seeks to persuade European nations to sign the Stroke Action Plan for Europe Declaration and lend their support to the fight against stroke throughout Europe as a symbol of their dedication to enhancing prevention, treatment, care, and assistance.

List of Key and Emerging Players in Stroke Disorder and Treatment Market

AbbVie
Medtronic
Pfizer
Bristol Myers Squibb
F. Hoffmann-La Roche
Amgen Inc
Biogen Inc
Boston Scientific Corporation
AstraZeneca
Royal Philips
Johnson & Johnson Services
GE Healthcare

Key Industry Developments

June 2026
Penumbra received U.S. FDA clearance for its Thunderbolt™ Computer-Assisted Vacuum Thrombectomy (CAVT) platform for the treatment of acute ischemic stroke, expanding its portfolio of advanced mechanical thrombectomy solutions.
June 2026
Medtronic completed the acquisition of Scientia Vascular, strengthening its neurovascular portfolio with advanced microcatheters and access technologies used in minimally invasive stroke treatment procedures.
April 2026
Bayer announced that China's National Medical Products Administration accepted the marketing authorization application for asundexian for the prevention of recurrent ischemic stroke in patients following non-cardioembolic ischemic stroke or transient ischemic attack.
December 2025
Silver Creek Pharmaceuticals announced positive mid-stage clinical trial results for SCP-776 in acute ischemic stroke and continued advancing the therapy under the U.S. FDA Fast Track designation to address patients beyond the conventional treatment window.
November 2025
The Central Drugs Standard Control Organisation (CDSCO) approved India's first indigenously developed Supernova stent retriever for acute ischemic stroke treatment following successful multicenter clinical trials, expanding locally developed neurointerventional treatment options.
September 2025
Zylox-Tonbridge continued expanding its neurovascular R&D pipeline with late-stage development programs covering thrombectomy stents, aspiration systems, intracranial drug-eluting stents and ischemic stroke prevention devices to broaden its stroke intervention offerings.
July 2025
Penumbra expanded the global commercialization of its advanced thrombectomy portfolio for acute ischemic stroke through additional international market launches and regulatory clearances, strengthening access to minimally invasive stroke treatment technologies.

Report Scope

Segmentation

By Type 2
  • Ischemic stroke
  • Hemorrhagic strokes
By Medicine 2
  • Anticoagulants
  • Anti-hypertensive
By Treatment 2
  • Tissue plasminogen activator (tPA)
  • Endovascular procedures

Geographies Covered

North America 2
  • U.S.
  • Canada
Europe 8
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Russia
  • Nordic
  • Benelux
APAC 7
  • China
  • Korea
  • Japan
  • India
  • Australia
  • Taiwan
  • South East Asia
Middle East and Africa 6
  • UAE
  • Turkey
  • Saudi Arabia
  • South Africa
  • Egypt
  • Nigeria
LATAM 5
  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Colombia
Competitive Coverage AbbVie · Medtronic · Pfizer · Bristol Myers Squibb · F. Hoffmann-La Roche
Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Report to Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

The stroke disorder and treatment market size is valued at USD 25.60 Billion in 2026 and is projected to reach USD 46.38 Billion by 2034, at a CAGR of 7.71% during the forecast period 2026-2034.

North America dominated the market with a share of 38% in 2025.

The leading players in this market are AbbVie, Medtronic, Pfizer, Bristol Myers Squibb, F. Hoffmann-La Roche.

The stroke disorder and treatment market is projected to grow at a CAGR of 7.71% during the forecast period of 2026 2034.
About the Author
Dhanashri Chandgude
Dhanashri Chandgude
Senior Research Associate

Dhanashri Chandgude is a healthcare research professional with over four years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.

Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.

Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Request Sample Order Report Now

We are featured on: